NASDAQ:COCP Cocrystal Pharma Q3 2026 Earnings Results & Report $0.98 -0.03 (-3.28%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.01 (+0.83%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cocrystal Pharma missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.20 versus the -$0.18 consensus estimate, while revenue of $110 thousand topped the $105 thousand estimate by $5.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeBefore Market Opens Cocrystal Pharma EPS ResultsActual EPS-$0.20Consensus EPS -$0.18Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCocrystal Pharma Revenue ResultsActual Revenue$110 thousandExpected Revenue$105 thousandBeat/MissBeat by +$5.00 thousandYoY Revenue GrowthN/AConference Call ResourcesSEC FilingEarnings HistoryCompany Profile Cocrystal Pharma Q3 2026 Earnings FAQ Did Cocrystal Pharma beat earnings estimates for Q3 2026? Cocrystal Pharma (NASDAQ:COCP) reported earnings of -$0.20 per share for Q3 2026, missing the consensus estimate of -$0.18. The report was announced on Monday, November 16, 2026. What was Cocrystal Pharma's revenue for Q3 2026? Cocrystal Pharma reported revenue of $110 thousand for Q3 2026, against a consensus estimate of $105 thousand. Cocrystal Pharma Earnings HeadlinesCOCP: Phase 1b norovirus challenge study results near year-end 2026November 18 at 12:30 PM | msn.comCocrystal Pharma Posts Wider Q3 Loss, Led By Norovirus Challenge Study CostsNovember 16 at 8:11 AM | rttnews.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 18 at 1:00 AM | Porter & Company (Ad)Cocrystal Q3 Loss Widens On Higher Costs; Norovirus Data Expected Near Year-EndNovember 16 at 8:11 AM | rttnews.comCocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial ResultsNovember 15 at 7:00 AM | globenewswire.comCocrystal Pharma (NASDAQ:COCP) Stock Crosses Above 200 Day Moving Average - Should You Sell?November 10, 2026 | americanbankingnews.comSee More Cocrystal Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email. Email Address About Cocrystal PharmaCocrystal Pharma (NASDAQ:COCP) is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments. Cocrystal Pharma is based in Bothell, Washington. It has concentrated on antiviral drug development rather than marketing commercial medicines, and its programs and research priorities may change as development progresses.View Cocrystal Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.